<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05110027</url>
  </required_header>
  <id_info>
    <org_study_id>MS200569_0040</org_study_id>
    <secondary_id>2021-004164-10</secondary_id>
    <nct_id>NCT05110027</nct_id>
  </id_info>
  <brief_title>Enpatoran Human Mass Balance and Absolute Bioavailability Study</brief_title>
  <official_title>Phase I, Open-Label, 2-Period, Single-Sequence Study to Evaluate the Mass Balance and Absorption, Disposition, Metabolism and Excretion of [14C]Enpatoran, and the Absolute Bioavailability of Enpatoran in Healthy Male Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of Period 1 of this study is to provide a definitive quantitative&#xD;
      characterization of the mass balance, and rates and routes of excretion of enpatoran, and to&#xD;
      determine and quantify enpatoran and its metabolites in excreta (urine and feces) and plasma.&#xD;
      The purpose of Period 2 of this study is to determine the absolute oral bioavailability of&#xD;
      enpatoran. Total minimum duration of study participation for each participant is&#xD;
      approximately 50 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2, 2021</start_date>
  <completion_date type="Anticipated">July 4, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 4, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Period 1: Percent Urinary Recovery (feurine) of Total Radioactivity per Sampling Interval</measure>
    <time_frame>-24-0 hours (pre-dose), 0-4, 4-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the intravenous (IV) dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Percent Fecal Recovery (fefeces) of Total Radioactivity per Sampling Interval</measure>
    <time_frame>-24-0 hours (pre-dose), 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the intravenous (IV) dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Percent Total Recovery in Urine and Feces (fetotal) of Total Radioactivity per Sampling Interval</measure>
    <time_frame>Urine: -24-0 hours (pre-dose), 0-4, 4-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours post-dose; Feces: -24-0 hours (pre-dose), 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours post-dose of IV injection</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Pharmacokinetic Plasma and Blood Concentration of Total Radioactivity</measure>
    <time_frame>Pre-dose (Day 1), 15, 30 minutes, 1, 1.5, 2.0, 4.0, 6.0, 8.0, 12, 24, 48, 72, 96, 120, 144, 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 1: Pharmacokinetic Plasma Concentration of Enpatoran</measure>
    <time_frame>Pre-dose (Day 1), 15, 30 minutes, 1, 1.5, 2.0, 4.0, 6.0, 8.0, 12, 24, 48, 72, 96, 120, 144, 168 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Period 2: Pharmacokinetic Plasma and Blood Concentration of [14C]Enpatoran and Enpatoran</measure>
    <time_frame>[14C]Enpatoran: Pre-dose, 5, 15, 30 minutes, 1, 1.5, 2, 4, 6, 8, 12, 24, 48, 72 hours post-dose; Enpatoran: Pre-dose, 30 minutes, 2, 4, 6, 8, 12, 24, 48, 72 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Period 1 and 2: Safety Profile as Assessed by Incidence of Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), Laboratory Variables, Vital Signs and Electrocardiogram (ECG) Measurements</measure>
    <time_frame>Period 1: Baseline up to Day 14; Period 2: Baseline up to Day 4</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Period 1: Enpatoran + [14C]enpatoran microtracer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: Enpatoran + [14C]enpatoran microdose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enpatoran</intervention_name>
    <description>Participants will receive single oral dose of enpatoran tablet on Day 1</description>
    <arm_group_label>Period 1: Enpatoran + [14C]enpatoran microtracer</arm_group_label>
    <arm_group_label>Period 2: Enpatoran + [14C]enpatoran microdose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]enpatoran microtracer</intervention_name>
    <description>Participants will receive single oral dose of non-labeled enpatoran solution spiked with microtracer of [14C]enpatoran on Day 1 of Period 1.</description>
    <arm_group_label>Period 1: Enpatoran + [14C]enpatoran microtracer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]enpatoran microdose</intervention_name>
    <description>Participants will receive intravenous [14C]enpatoran microdose administered at 1.5 hours after the oral dose of enpatoran on Day 1 of Period 2.</description>
    <arm_group_label>Period 2: Enpatoran + [14C]enpatoran microdose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are overtly healthy as determined by medical evaluation, including medical history,&#xD;
             physical examination, laboratory tests, and cardiac monitoring (blood pressure, heart&#xD;
             rate and 12-lead electrocardiogram)&#xD;
&#xD;
          -  Have a body weight within 50 to 110 kilogram (kg) and Body mass index (BMI) within the&#xD;
             range ≥ 18.0 and ≤ 30.0 kilogram per meter square (kg/m^2)&#xD;
&#xD;
          -  Other protocol defined inclusion criteria could apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History or presence of clinically relevant respiratory, gastrointestinal, renal,&#xD;
             hepatic, hematological, lymphatic, neurological, cardiovascular, psychiatric,&#xD;
             musculoskeletal, genitourinary, immunological, dermatological, connective tissue&#xD;
             diseases or disorders&#xD;
&#xD;
          -  Prior history of cholecystectomy or splenectomy, and any clinically relevant surgery&#xD;
             within 6 months prior to Screening&#xD;
&#xD;
          -  Any surgical or medical condition which might significantly alter the absorption,&#xD;
             distribution, metabolism and excretion (ADME) of drugs, or which may jeopardize the&#xD;
             participant in case of participation in the study&#xD;
&#xD;
          -  History of any malignancy&#xD;
&#xD;
          -  History or presence of epilepsy, neurological disorders with seizure propensity or&#xD;
             undiagnosed loss of consciousness, severe head trauma within 6 months or severe&#xD;
             depression within 12 months prior to Screening), or neuropsychiatric conditions&#xD;
&#xD;
          -  History of chronic or recurrent acute infection or any bacterial, viral, parasitic or&#xD;
             fungal infections within 30 days prior to Screening and at any time between Screening&#xD;
             and admission, or hospitalization due to infection within 6 months prior to Screening,&#xD;
             or a history of herpes zoster within 12 months prior to Screening.&#xD;
&#xD;
          -  History of drug hypersensitivity ascertained or presumptive allergy/hypersensitivity&#xD;
             to the active drug substance and/or formulation ingredients; history of serious&#xD;
             allergic reactions leading to hospitalization or any other hypersensitivity reaction&#xD;
             in general, which may affect the safety of the participant and/or outcome of the study&#xD;
             per the Investigator's discretion&#xD;
&#xD;
          -  History of alcoholism or drug abuse within 1 year prior to Screening, or evidence of&#xD;
             such abuse as indicated by the laboratory assays conducted during Screening&#xD;
&#xD;
          -  Any condition, including findings in the laboratory tests, medical history, or other&#xD;
             Screening assessments, that in the opinion of the Investigator constitutes an&#xD;
             inappropriate risk or a contraindication for participation in the study or that could&#xD;
             interfere with the study's objectives, conduct, or evaluation&#xD;
&#xD;
          -  Other protocol defined exclusion criteria could apply&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Groningen</city>
        <zip>9702</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 27, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Microtracer</keyword>
  <keyword>Microdose</keyword>
  <keyword>Clinical Pharmacology</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https:\\bit.ly/IPD21</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

